Edition:
United States

Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

177.18USD
26 May 2017
Change (% chg)

$-7.64 (-4.13%)
Prev Close
$184.82
Open
$180.50
Day's High
$180.91
Day's Low
$176.83
Volume
479,532
Avg. Vol
325,944
52-wk High
$209.20
52-wk Low
$161.09

SHPG.OQ

Chart for SHPG.OQ

About

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas... (more)

Overall

Beta: 1.62
Market Cap(Mil.): $53,583.92
Shares Outstanding(Mil.): 302.34
Dividend: 0.77
Yield (%): 0.52

Financials

  SHPG.OQ Industry Sector
P/E (TTM): 63.65 29.41 30.38
EPS (TTM): 2.76 -- --
ROI: 1.70 13.85 13.36
ROE: 3.11 14.79 14.50

BRIEF-Xenetic Biosciences receives update from Shire's Phase 1/2 study evaluating SHP656 in development as long-acting treatment for Hemophilia A

* Xenetic Biosciences - receives program update from partner Shire's phase 1/2 study evaluating SHP656 in development as a long-acting treatment for Hemophilia A

May 22 2017

Shire's swelling disorder drug moves closer to U.S. approval

Successful late-stage data on Shire Plc's, long-acting preventative treatment for hereditary angioedema (HAE) brings the Dublin-based drugmaker one step closer to U.S. approval, it said on Thursday.

May 18 2017

UPDATE 3-Shire's swelling disorder drug moves closer to U.S. approval

* U.S. shares rise 3.4 pct, UK stock up 1.7 pct (Adds conference call details, analyst comment; updates shares)

May 18 2017

BRIEF-Shire expects to file potential EU marketing submission for lanadelumab in H1 2018

* Shire says potential EU marketing submission for lanadelumab is expected to be filed in first half of 2018, pending discussion with the EMA

May 18 2017

BRIEF-Shire's angioedema drug succeeds in late-stage study

* Shire's investigational treatment lanadelumab reduces hereditary angioedema monthly attack rate by 87% versus placebo in phase 3 26-week pivotal trial

May 18 2017

Shire's angioedema drug succeeds in late-stage study

May 18 Shire Plc said on Thursday its drug for hereditary angioedema (HAE), a disorder characterized by recurrent episodes of severe swelling, was successful in a late-stage study.

May 18 2017

Shire drives down costs to deliver earnings beat

LONDON Pharmaceutical group Shire , which bought hemophilia specialist Baxalta last year, reported a better-than-expected 14 percent rise in first-quarter earnings, helped by cost savings and higher sales of its rare disease drugs.

May 02 2017

UPDATE 2-Shire drives down costs to deliver earnings beat

* Shares rise 3 pct to top FTSE 100 index (Adds CEO comments, analyst reaction, updates shares)

May 02 2017

Shire delivers first-quarter beat with 14 pct rise in earnings

LONDON, May 2 Shire, the pharma group that bought haemophilia specialist Baxalta last year, reported a better-than-expected 14 percent rise in first-quarter earnings, helped by higher sales of rare disease drugs and demand for its new dry eye medicine.

May 02 2017

BRIEF-Shire and Parion Sciences enter into a collaborative license agreement

* Shire and Parion Sciences enter into a collaborative license agreement to advance p-321 for ophthalmic indications

May 01 2017

More From Around the Web

Earnings vs. Estimates